• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Canertinib Dihydrochloride

Canertinib Dihydrochloride

Product ID C0252
Cas No. 289499-45-2
Purity ≥98%
Product Unit SizeCostQuantityStock
25 mg $135.00 Please Inquire
100 mg $404.00 In stock
250 mg $809.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Canertinib is an irreversible inhibitor of EGFR (HER2/ErbB). This compound is currently in clinical trials as an anticancer chemotherapeutic, displaying activity against a variety of cancers. In a cellular model of melanoma, canertinib exhibits cytostatic activity, stopping cell growth in the G1 phase, but not inducing apoptosis except at very high concentrations. In a related animal model, canertinib inhibits tumor growth. Separately, canertinib inhibits Akt and ERK1/2 in cells lacking ErbB receptors and induces caspase-mediated apoptosis.

Product Info

Cas No.

289499-45-2

Purity

≥98%

Formula

C24H25ClFN5O3 • 2HCl

Formula Wt.

558.86

Chemical Name

N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6- yl]prop-2-enamide;dihydrochloride

IUPAC Name

N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6- yl]prop-2-enamide;dihydrochloride

Synonym

CI1033

Appearance

Pale yellow powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

C0252 MSDS PDF

Info Sheet

C0252 Info Sheet PDF

Brochures

PI3K-Akt-mTORC Pathway Booklet

Ras-Raf-MEK-ERK Pathway Booklet

References

Djerf Severinsson EA, Trinks C, Gréen H, et al. The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo. Biochem Biophys Res Commun. 2011 Oct 28;414(3):563-8. PMID: 21982771.

Trinks C, Severinsson EA, Holmlund B, et al. The pan-ErbB tyrosine kinase inhibitor canertinib induces caspase-mediated cell death in human T-cell leukemia (Jurkat) cells. Biochem Biophys Res Commun. 2011 Jul 8;410(3):422-7. PMID: 21669187.

Zinner RG, Nemunaitis J, Eiseman I, et al. Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res. 2007 May 15;13(10):3006-14. PMID: 17505003.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • C2900

    CH5424802

    ALK inhibitor.

    ≥99%
  • A0916

    Acepromazine Maleate

    Phenothiazine derivative; D1/2 and 5-HT1A/2A an...

    ≥99%
  • A4002

    AK-7

    SIRT2 inhibitor.

    ≥98%
  • M1779

    Methyldopa Sesquihydrate

    DOPA decarboxylase inhibitor, indirect α2-adre...

    ≥98%
  • M2077

    1-Methoxy-5-methylphenazinium Methyl Sulfate

    Electron carrier used to study dehydrogenase el...

    ≥98%
  • P2512

    S-(N-Phenethylthiocarbamoyl)-L-cysteine

    Cysteine-ITC conjugate, antioxidant.

    ≥98%
  • F130280

    FHD-286

    BRG1/BRM ATPase inhibitor

    ≥98%
  • O938565

    6-Oxodocetaxel

    Docetaxel impurity

    ≥98%
  • A5161

    Ampiroxicam

    Piroxicam prodrug, NSAID; COX-1/2 inhibitor.

    ≥98%
  • M1676

    Methotrexate Hydrate

    DHF reductase inhibitor.

    ≥98%
  • C577524

    Concanamycin A

    Macrolide lactone antibiotic.

    ≥98%
  • S7871

    Stresscopin, human

    Peptide, urocortin III analog; CRFR2 agonist.

    ≥95%
  • V3326

    Virginiamycin S1

    Macrolide antibiotic; peptidyl transferase inhi...

    ≥99%
  • T6831

    Triadimenol

    Triadimefon metabolite; mutagen.

    ≥96%
  • E0403

    Ebastine

    Histamine H1 antagonist.

    ≥98%
  • I4961

    Imperatorin

    Furocoumarin; voltage-gated Na+ channel blocker...

    ≥98%
  • H9661

    Hypocrellin A

    Prevents MHC II antigen presentation.

    ≥77%, contains ~16% B
  • B1955

    Benztropine Mesylate

    DAT inhibitor.

    ≥99%
  • R0248

    Ramatroban

    CRTH2 inhibitor, TxA2 antagonist.

    ≥98%
  • D1759

    Deoxynivalenol

    Trichothecene mycotoxin produced by Fusarium.

    ≥98%, TLC

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only